AbstractObjectivesThis study is aimed to evaluate the protective effects of GGX on lung injury of Chronic Obstructive Lung Disease (COPD) mice model.
Materials and MethodsC57BL/6 mice were challenged with lipopolysaccharide (LPS) and cigarette smoke extract (CSE) and then treated with vehicle only (Control group), dexamethasone 3 mg/kg (Dexa group), gam-gil-tang 200 mg/kg (GGT group), GGX 100, 200, and 400 mg/kg (GGX group). After sacrifice, its bronchoalveolar lavage fluid (BALF) or lung tissue was analyzed with cytospin, Enzyme-Linked Immunosorbent Assay (ELISA), real-time polymerase chain reaction (PCR) and hematoxylin & eosin (H&E), and Masson’s trichrome staining.
참고문헌1. Park YB, Rhee CK, Yoon HK, Oh YM, Lim SY, Lee JH, et al. 2018; COPD clinical practice guideline of the Korean Academy of Tuberculosis and Respiratory Disease: a summary. Tuberc Respir Dis (Seoul). 81:261–73.
2. Barnes PJ, Shapiro SD, Pauwels RA. 2003; Chronic obstructive pulmonary disease: molecular and cellular mechanisms. Eur Respir J. 22:4. 672–88.
3. Kim IA, Park YB, Yoo KH. 2004; Pharmacotherapy for chronic obstructive pulmonary disease. J Korean Med Assoc. Sep. 61:9. 545–551.
4. Anthonisen NR, Connett JE, Kiley JP, Altose MD, Bailey WC, Buist AS, et al. 1994; Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1: the Lung Health Study. JAMA. 272:1497–505.
5. Singh S, Amin AV, Loke YK. 2009; Long-term use of inhaled corticosteroids and the risk of pneumonia in chronic obstructive pulmonary disease: a meta-analysis. Arch Intern Med. 169:219–29.
6. Barnes PJ. 2013; New anti-inflammatory targets for chronic obstructive pulmonary disease. Nat Rev Drug Discov. 12:7. 543–59.
7. Lee ES, Han JM, Kim MH, Namgung U, Yeo Y, Park YC. 2013; Effects of inhalable microparticles of Socheongryong-tang on chronic obstructive pulmonary disease in a mouse model. J Korean Med. 34:3. 54–68.
8. Lee JG, Yang SY, Kim MH, Namgung U, Park YC. 2011; Protective effects of Socheongryong-tang on elastase-induced lung injury. J Korean Oriental Med. 32:4. 83–99.
9. Kim Y, Yang SY, Kim MH, Namgung U, Park YC. 2011; Effects of Saengmaekcheongpye-eum on LPS-induced COPD model. Korean J Oriental Int Med. 2011; 32:2. 217–31.
10. Kim HW, Yang SY, Kim MH, Namgung U, Park YC. 2011; Protective effects of Maekmundong-tang on elastase-induced lung injury. J Korean Oriental Med. 32:2. 63–78.
11. Lee H, Kim Y, Kim HJ, Park S, Jang YP, Jung S, et al. 2012; Herbal Formula, PM014, Attenuates Lung Inflammation in a Murine Model of Chronic Obstructive Pulmonary Disease. Evid Based Complement Alternat Med. 2012; 769830
12. Han JM, Yang WK, Kim SH, Park YC. 2015; Effects of Sagan-tang and individual herbs on COPD mice model. J Korean Med Soc Herb Formula Study. 23:2. 171–87.
13. Park JJ, Yang WK, Lyu YR, Kim SH, Park YC. 2019; Inhibitory effects of SGX01 on lung injury of COPD mice model. Korean J Int Korean Med. 40:4. 567–81.
14. Yang WK, Lyu YR, Kim SH, Park YC. 2018; Effects of GHX02 on Chronic Obstructive Pulmonary Disease Mouse Model. J Korean Med. 39:4. 126–35.
15. Kim SH, Hong JH, Yang WK, Geum , et al. 2020; Herbal combinational medication of Glycyrrhiza glabra, Agastache rugosa containing Glycyrrhizic acid, Tilianin inhibits Neutrophilic lung inflammation by affecting CXCL2, Interleukin-17/STAT3 signal pathways in a murine model of COPD. Nutrients. 12:4. 926
16. Yang L, Li J, Li Y, Tian Y, Li S, Jiang , et al. 2015; Identification of metabolites and metabolic pathways related to treatment with Bufei Yishen formula in a rat COPD model using HPLC Q-TOF/MS. Evidence-Based Complementary and Alternative Medicine, 2015.
17. Hwang DY. 1986. Bang-yak-hap-pyeon. Seoul: Namsandang;p. 240
18. Lyu YR. 2020. Inhibitory effects of GGX in a particulate matter-induced lung injury mouse model. doctoral dissertation. Daejeon university.
19. Hong HW. 2011. The Effects of Kamgiltang on Passive Smoking in Rats. doctoral dissertation. Dong-eui University.
20. Mizutani N, Fuchikami J, Takahashi M, Nabe T, Yoshino S, Kohno S. 2009; Pulmonary emphysema induced by cigarette smoke solution and lipopolysaccharide in guinea pigs. Biol Pharm Bull. 32:9. 1559–64.
21. Lopez AD, Shibuya K, Rao C, Mathers CD, Hansell AL, Held LS, et al. 2006; Chronic obstructive pulmonary disease: current burden and future projections. Eur Rspir J. 27:2. 397–412.
22. Mathers CD, Loncar D. 2006; Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 3:11. e442
23. An TJ, Yoon HK. 2018; Prevalence and socioeconomic burden of chronic obstructive pulmonary disease. J Korean Med Assoc. 61:9. 533–8.
24. GBD 2015 Chronic Respiratory Disease Collaborators. 2017; Global, regional, and national deaths, prevalence, disability adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990–2015 a systematic analysis for the Global Burden of Disease Study 2015. Lancet Respir Med. 5:9. 691–706.
25. Jung YM, Lee H. 2011; Chronic obstructive pulmonary disease in Korea: Prevalence, risk factors, and quality of life. J Korean Acad Nurs. 41:2. 149–56.
26. Ministry of Gender Equality & Family (MOGEF). 2014. 2014 Comprehensive survey on the contact with the harmful environment for youth. Available at: URL: http://www.mogef.go.kr
Accessed April 1.
27. Yoon J, Seo H, Oh IH, Yoon SJ. 2016; The Non-Communicable Disease Burden in Korea: Findings from the 2012 Korean Burden of Disease Study. J Korean Med Sci. Nov. 31:Suppl 2. S158–S167.
28. Park SK. 2002; Chronic obstructive pulmonary disease - definition, severity, risk factors, etiology, pathology, diagnosis. J Korean Med. 63:2. 389–99.
29. Lurwidya F, Damayanti T, Yunus F. 2016; The Role of Innate and Adaptive Immune Cells in the Immunopathogenesis of Chronic Obstructive Pulmonary Disease. Tuberc Respir Dis(Seoul). 79:1. 5–13.
30. Lee S, et al. 2007; Antielastin autoimmunity in tobacco smokinginduced emphysema. Nature Med. 13:567–569.
31. Yoo CG. 2009; Pathogenesis and pathophysiology of COPD. Korean J Med. 77:4. 383–400.
33. Majo J, Ghezzo H, Cosio MG. 2001; Lymphocyte population and apoptosis in the lungs of smokers and their relation to emphysema. Eur Respir J. 17:946–53.
34. Barnes PJ. 2008; The cytokine network in asthma and chronic obstructive pulmonary disease. J Clin Invest. 118:11. 3546–56.
35. Rovina N, Koutsoukou A, Koulouris NG. 2013; Inflammation and immune response in COPD: where do we stand? Mediators Inflammation. 2013; 413735
36. Herbology Editorial Committee of Korean Medicine schools. 1991. Boncho-hak. Seoul: Younglimsa;p. 124–5. p. 136–7. p. 214–5. p. 448–9. p. 534–5. p. 580–1. p. 588–9.
37. Park YC, Jin M, Kim SH, Kim MH, et al. 2014; Effects of inhalable microparticle of flower of Lonicera japonica in a mouse model of COPD. Journal of Ethnopharmacology. 151:1. 123–130.
38. Di Stefano A, Capelli A, Lusuardi M, Balbo P, Vecchio C, Maestrelli P, et al. 1998; Severity of airflow limitation is associated with severity of airway inflammation in smokers. Am J Respir Crit Care Med. 158:4. 1277–85.
39. Aaron SD, Angel JB, Lunau M, Wright K, Fex C, Le Saux N, et al. 2001; Granulocyte inflammatory markers and airway infection during acute exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 163:2. 349–55.
40. Deveci Y, Deveci F, Ilhan N, Karaca I, Turgut T, Muz MH. 2010; Serum ghrelin, IL-6 and TNF-α levels in patients with chronic obstructive pulmonary disease. Tuberk Toraks. 58:2. 162–72.
42. Levänen B, Glader P, Dahlén B, Billing B, Qvarfordt I, Palmberg L, et al. 2016; Impact of tobacco smoking on cytokine signaling via interleukin-17A in the peripheral airways. Int J Chron Obstruct Pulmon Dis. 11:2109–16.
43. Lukacs NW, Hogaboam CM, Kunkel SL. 2005; Chemokines and their receptors in chronic pulmonary disease. Curr Drug Targets Inflamm Allergy. 4:3. 313–7.
|
|